07 dec: 5 fede bordlamper
09 dec: Skandalen ingen taler om
07-12-2010 13:00:00

Ultralife Corporation Receives $5.5 Million Land Warrior Battery and Charging System Contract

Relateret indhold

Ultralife Corporation (NASDAQ: ULBI) has received a contract valued at

approximately $5.5 million to supply its suite of Land Warrior Lithium

non-rechargeable batteries and rechargeable Lithium Ion batteries and

charging systems from a major international defense contractor for use

with the Land 200 Battle Management System by the Australian military.

Deliveries are expected to begin in the first quarter of 2011 and be

completed by the fourth quarter of 2012.

“Our capabilities in developing and supplying technically-advanced

defense communications and power systems, which we have demonstrated to

the U.S. Department of Defense across a wide variety of military

programs, are increasingly being recognized by our international

allies,” said John D. Kavazanjian, president and chief executive

officer. “In this case, our Land Warrior product suite will be used to

support the Australian military’s Land 200 Battle Management System, a

program for which we are already supplying our A320 RF pocket

amplifiers.”

Land Warrior is an integrated, modular fighting system that uses

technology to enhance individual soldiers’ close-combat tactical

awareness, lethality and survivability. The system includes

weapon-mounted sensors, an integrated helmet assembly, a

communications-navigation computer system and software for

friendly-force tracking and command/control programs, and it

incorporates Ultralife’s battery models LI-145, LI-80, LM-145 and CH0006

Charger and Adapters.

About Ultralife Corporation

Ultralife Corporation, which began as a battery company, serves its

markets with products and services ranging from portable and standby

power solutions to communications and electronics systems. Through its

engineering and collaborative approach to problem solving, Ultralife

serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the company’s business segments

include: Battery & Energy Products, Communications Systems and Energy

Services. Ultralife has operations in North America, Europe and Asia.

For more information, visit www.ultralifecorp.com

This press release may contain forward-looking statements based on

current expectations that involve a number of risks and uncertainties.

The potential risks and uncertainties that could cause actual results to

differ materially include: worsening global economic conditions,

increased competitive environment and pricing pressures, disruptions

related to restructuring actions and delays. The Company cautions

investors not to place undue reliance on forward-looking statements,

which reflect the Company’s analysis only as of today’s date. The

Company undertakes no obligation to publicly update forward-looking

statements to reflect subsequent events or circumstances. Further

information on these factors and other factors that could affect

Ultralife's financial results is included in Ultralife's Securities and

Exchange Commission (SEC) filings, including the latest Annual Report on

Form 10-K.

Ultralife Corporation

Philip

Fain, 315-332-7100

pfain@ulbi.com

or

Investor

Relations:

Lippert/Heilshorn & Associates,

Inc.

Jody Burfening, 212-838-3777

jburfening@lhai.com

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY

24-03-2017 13:31:36
Udvalget for humanmedicinske lægemidler (CHMP) ved Det Europæiske Lægemiddelsagentur (EMA) har tildelt Novo Nordisks Refixia en positiv udtalelse og anbefaler en markedsføringstilladelse.Det skriver Novo Nordisk i en fondsbørsmeddelelse.CHMP anbefaler en markedsføringstilladelse til Refixia til unge og voksne med hæmofili B. Til grund for anbefalingen ligger resultater fra udviklingsprogrammet par..

Novo/Exane: Kursmålet skæres til 270 kr.

24-03-2017 10:17:22
Den franske storbank Exane BNP Paribas skærer kursmålet for aktien i Novo Nordisk til 270 kr. fra 295 kr. Anbefalingen er uændret "outperform", viser data fra Bloomberg.Novo-aktien falder fredag 0,4 pct., eller 1 kr., til 233,20 kr. Det dækker dog over en stigning, da aktien ikke længere handles inklusive retten til et udbytte på 4,60 kr./ritzau/FINANSJakob Dalskov +45 33 30 03 35 Ritzau Finans, E..

Aktier/tendens: Mulighed for mere gas til Mærsk i ventet rødt C20

24-03-2017 08:31:54
Det danske aktiemarked kan fredag blive præget af små udsving med en lille overvægt af negative fortegn.A.P. Møller-Mærsks B-aktie var uændret efter torsdagens handel og blev handlet til 11.500 kr. Aktien kan dog gå fra grå til grøn fredag, da der er potentielt gode nyheder til det danske konglomerat.Efter en Nordsø-aftale, der kan redde det ellers lukningstruede Tyra-felt, skriver Jyllands-Posten..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Nordea har fældet hemmelig dom over PostNords kvaler
2
Fredagens aktier: C20 Cap i slutspurt mens Dong steg til vejrs
3
Aktier/Sydbank: Forventningerne til C25 Cap-indekset løftes
4
Trumps sundhedsreform rykker nærmere afstemning
5
Republikansk komitéformand afviser Trump-anklage mod Obama

Relaterede aktiekurser

Ultralife Corporation 5,4500 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. marts 2017 16:38:57
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB5 - 2017-03-25 16:38:57 - 2017-03-25 16:38:57 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x